1399. Clarithromycin–Rifampin-based Treatment for Non-tuberculous Mycobacterial Infections in Immunocompromised Patients Who Require Concomitant CYP-Metabolized Medications

BACKGROUND: Non-tuberculous mycobacteria (NTM) are causes of pulmonary and extrapulmonary disease that frequently affect immunocompromised hosts (ICH). Current treatment guidelines recommend a macrolide-based, multi-drug regimen that includes rifampin. Rifampin is a potent cytochrome P450 (CYP) 3A i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Bocco, Isabel H, Aleissa, Muneerah M, Cheng, Matthew, Manne-Goehler, Jennifer, Marty, Francisco M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643767/
http://dx.doi.org/10.1093/ofid/ofab466.1591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643767/
http://dx.doi.org/10.1093/ofid/ofab466.1591

Ejemplares similares